da geht mit Sicherheit noch einiges!
Press Release Source: Nymox Pharmaceutical Corporation
Nymox Reports Second Quarter 2005 Financial Results
Monday August 15, 12:22 pm ET
Product Sales Increased by 63% over Second Quarter 2004
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Aug. 15, 2005--Nymox Pharmaceutical Corporation (NASDAQ: NYMX - News) announced today its financial results for the second quarter of 2005. Nymox reported a net loss of $847,299, or $0.03 per share, for the quarter compared to $1,142,540, or $0.05 per share, for the same period in 2004, and $1,804,976, or $0.07 per share, for the six months ended June 30, 2005, compared to $2,106,322, or $0.09 per share, for the six months ended June 30, 2004. Product sales increased by 63% for the second quarter and 55% for the first six months of 2005 compared to the same periods in 2004. Product sales for the first six months of 2005 amounted to $218,314, compared to $141,254 for the same period in 2004. Nymox currently has $10.2 million in financing available from its most recent October 6, 2004 financing. The weighted, diluted average number of common shares at June 30, 2005 was 25,763,887, compared to 24,920,579 at June 30, 2004.
ADVERTISEMENT
Nymox Pharmaceutical Corporation is a biopharmaceutical company with three unique proprietary products on the market, and a significant R&D pipeline of drug products in development. Nymox developed and is currently offering its AlzheimAlert(TM) test, a nationally certified clinical reference laboratory urinary test that is the world's only accurate, non-invasive aid in the diagnosis of Alzheimer's disease. The AlzheimAlert(TM) test is certified with a CE Mark, making the device eligible for sale in the European Union. Nymox also developed and markets NicAlert(TM) and TobacAlert(TM); tests that use urine or saliva to detect use of and exposure to tobacco products. NicAlert(TM) has received clearance from the FDA. TobacAlert(TM) is the first test of its kind to accurately measure second hand smoke exposure in individuals. The Company's TobacAlert(TM) product is presently available in CVS/pharmacy® stores across the U.S.. Nymox has signed distribution deals for AlzheimAlert(TM) with Alifax S.p.A. in Italy, with KlinLab, Ltd. in the Czech Republic, and with B. Caravitis S.A. in Greece. Nymox is developing NX-1207, a novel treatment for benign prostatic hyperplasia. NX-1207 has shown statistically significant positive results in Phase 1 and 2 clinical trials in the U.S. NX-1207 is currently in late stage Phase 2 human testing in the US. Nymox has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company is developing new antibacterial agents for the treatment of urinary tract and other bacterial infections in humans and for the treatment of E. coli O157:H7 contamination in food products. Nymox also is developing drug treatments aimed at the causes of Alzheimer's disease and has several other drug candidates and diagnostic technologies in development.
More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
--------------------------------------------------
Contact:
Nymox Pharmaceutical Corporation
Roy Wolvin, 1-800-93NYMOX
www.nymox.com
|
|
2 |
3 |
4 |
5 |
6
| 6
Thread abonnieren
